Novavax (NVAX) Reports Q4 EPS of ($11.28), Guides 2022 Revenue of $4-$5B

Novavax (NASDAQ: NVAX) reported Q4 EPS of ($11.28), $10.73 worse than the analyst estimate of ($0.55). Revenue for the quarter came in at $222 million versus the consensus estimate of $442.77 million.

GUIDANCE:

Novavax sees FY2022 revenue of $4-5 million.

For earnings history and earnings-related data on Novavax (NVAX) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• UiPath Inc. (PATH) Reports In-Line Q2 EPS; offers guidance
• Torrid Holdings Inc. (CURV) Tops Q2 EPS by 8c; Offers Guidance